Inventor · disambiguated record
David Adam Savitsky
Also filed as: SAVITSKY DAVID A · SAVITSKY DAVID ADAM
24 granted patents·8 pending applications·85 citations·filing 2016–2025
95Inventor score
Files withAGENUS INC32
Top patents by PatentIndex Score
32 records- 0197US10912831B1Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Feb 9, 2021·6 cites·26 claims
- 0296US11638755B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted May 2, 2023·4 cites·20 claims
- 0396US10626181B2Nucleic acids encoding anti-OX40 antibodiesAGENUS INC·Filed 2019·Granted Apr 21, 2020·7 cites·35 claims
- 0495US10259882B2Anti-OX40 antibodiesAGENUS INC·Filed 2016·Granted Apr 16, 2019·16 cites·47 claims
- 0594US11242385B2Anti-CD137 antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted Feb 8, 2022·8 cites·24 claims
- 0694US10144779B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2016·Granted Dec 4, 2018·12 cites·92 claims
- 0793US11013802B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2017·Granted May 25, 2021·5 cites·21 claims
- 0892US11267889B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Mar 8, 2022·2 cites·26 claims
- 0992US10882908B2Anti-LAG-3 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Jan 5, 2021·2 cites·36 claims
- 1092US10479833B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2018·Granted Nov 19, 2019·8 cites·34 claims
- 1189US11345755B2Anti-PD-1 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted May 31, 2022·2 cites·25 claims
- 1289US10844119B2Anti-LAG-3 antibodies and methods of use thereofAGENUS INC·Filed 2017·Granted Nov 24, 2020·3 cites·32 claims
- 1388US2025206818A1Anti-lag-3 antibodies and methods of use thereofAGENUS INC·Filed 2024·Application pending·0 cites
- 1486US10323091B2Anti-PD-1 antibodies and methods of use thereofAGENUS INC·Filed 2016·Granted Jun 18, 2019·5 cites·94 claims
- 1585US12246066B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2023·Granted Mar 11, 2025·0 cites·19 claims
- 1685US11472883B2Methods of administering anti-OX40 antibodiesAGENUS INC·Filed 2020·Granted Oct 18, 2022·1 cites·15 claims
- 1785US11332536B2Vectors comprising nucleic acids encoding anti-OX40 antibodiesAGENUS INC·Filed 2020·Granted May 17, 2022·1 cites·22 claims
- 1884US11993653B2Antibodies and methods of use thereofAGENUS INC·Filed 2019·Granted May 28, 2024·2 cites·19 claims
- 1984US11136404B2Anti-OX40 antibodiesAGENUS INC·Filed 2019·Granted Oct 5, 2021·1 cites·64 claims
- 2084US2023167186A1Methods of administering anti-ox40 antibodiesAGENUS INC·Filed 2022·Application pending·0 cites
- 2184US2023108348A1Methods of administering anti-ox40 antibodiesAGENUS INC·Filed 2022·Application pending·0 cites
- 2279US12492257B2Anti-CTLA-4 antibodies and methods of use thereofAGENUS INC·Filed 2022·Granted Dec 9, 2025·0 cites·20 claims
- 2379US2022098316A1Anti-ox40 antibodies and methods of use thereofAGENUS INC·Filed 2021·Application pending·0 cites
- 2478US12492393B2Anti-CD137 antibodies and methods of use thereofAGENUS INC·Filed 2021·Granted Dec 9, 2025·0 cites·28 claims
- 2576US2022372149A1Anti-pd-1 antibodies and methods of use thereofAGENUS INC·Filed 2022·Application pending·0 cites
- 2675US12187795B2Anti-LAG-3 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Jan 7, 2025·0 cites·18 claims
- 2775US2025360209A1Anti-ctla-4 antibodies and methods of use thereofAGENUS INC·Filed 2025·Application pending·0 cites
- 2874US11993651B2Anti-lag-3 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted May 28, 2024·0 cites·15 claims
- 2974US11098117B2Anti-CD137 antibodies and methods of use thereofAGENUS INC·Filed 2020·Granted Aug 24, 2021·0 cites·25 claims
- 3074US2022106581A1Anti-cd137 antibodies and methods of use thereofAGENUS INC·Filed 2021·Application pending·0 cites
- 3166US10450373B2Anti-PD-1 antibodies and methods of use thereofAGENUS INC·Filed 2019·Granted Oct 22, 2019·0 cites·30 claims
- 3263US2025109201A1Anti-ilt2 antibodies and uses thereofAGENUS INC·Filed 2024·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →